A clinical trial shows a pill almost doubled survival for pancreatic cancer patients. Now what?

Article excerpt

A clinical trial found that daraxontrasib, an experimental pill, nearly doubled survival rates in pancreatic cancer patients, a disease that kills roughly 95 percent of those diagnosed within five years. The drug targets a specific genetic mutation found in about 10 percent of pancreatic cancers, showing median survival of 8.5 months versus 4.3 months in the control group. Researchers now face the challenge of moving the therapy toward FDA approval and determining how to identify which patients carry the mutation before treatment begins.